Biogen Finalizes Apellis Takeover

Biogen closes its takeover of Apellis, gaining SYFOVRE and EMPAVELI while expanding its rare disease and kidney disease portfolio

1

Biogen has acquired Apellis Pharmaceuticals, enhancing its portfolio with two commercial drugs and expanding into nephrology.
2

Apellis is now a wholly owned subsidiary of Biogen, following a successful tender offer for approximately 82.4% of its shares.
3

Apellis shareholders will receive $41 per share in cash, plus a contingent value right worth up to $4 per share based on future sales.
4

The acquisition is expected to boost Biogen's earnings growth and become accretive to non-GAAP diluted earnings per share by 2027.
5

Biogen aims to leverage Apellis' infrastructure to support the future launch of felzartamab for kidney transplant patients.

1